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SUMMARY
Normal platelet function is critical to blood hemostasis and maintenance of a closed circulatory 
system. Heightened platelet reactivity, however, is associated with cardiometabolic diseases and 
enhanced potential for thrombotic events. We now show gut microbes, through generation of 
trimethylamine N-oxide (TMAO), directly contribute to platelet hyperreactivity and enhanced 
thrombosis potential. Plasma TMAO levels in subjects (N>4000) independently predicted incident 
(3 yr) thrombosis (heart attack, stroke) risk. Direct exposure of platelets to TMAO enhanced 
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submaximal stimulus-dependent platelet activation from multiple agonists through augmented 
Ca2+ release from intracellular stores. Animal model studies employing dietary choline or TMAO, 
germ-free mice, and microbial transplantation, collectively confirm a role for gut microbiota and 
TMAO in modulating platelet hyperresponsiveness and thrombosis potential, and identify 
microbial taxa associated with plasma TMAO and thrombosis potential. Collectively, the present 
results reveal a previously unrecognized mechanistic link between specific dietary nutrients, gut 
microbes, platelet function, and thrombosis risk.
INTRODUCTION
Cardiovascular arterial thrombotic events, such as myocardial infarction and stroke, are a 
leading cause of disability and mortality. Platelet activation, aggregation and the subsequent 
generation of an occlusive intra-arterial thrombus are essential steps in atherothrombotic 
disease, and enhanced platelet reactivity is associated with both the extent of end organ 
injury and adverse prognosis (Frossard et al., 2004; Tantry et al., 2013). Platelet 
hyperreactivity and thrombosis risk are enhanced in the setting of numerous conditions 
associated with atherosclerotic heart disease, such as hyperlipidemia, oxidant stress, and 
hyperglycemia (Podrez et al., 2007; Chen et al., 2008; Zhu et al., 2012a). Understanding the 
mechanisms through which platelets become hyper-responsive and more prone to clot 
formation is therefore of considerable importance (Jennings, 2009).
The past decade has witnessed a rapidly growing awareness of the involvement of gut 
microbial organisms in the development of numerous cardiometabolic phenotypes (Bäckhed 
et al., 2004; Turnbaugh et al., 2006; Cox et al., 2014). For example, recent studies reveal 
participation of gut microbes in a metaorganismal pathway that contributes to the 
development of atherosclerosis (Wang et al., 2011; Koeth et al., 2013; Tang et al., 2013; 
Gregory et al., 2015). Briefly, specific trimethylamine (TMA) containing dietary nutrients, 
such as phosphatidylcholine, choline, and carnitine, can be used by gut microbes as a carbon 
fuel source. A waste product produced is TMA, which is carried via the portal circulation to 
the liver where it is rapidly converted by a family of enzymes, host hepatic flavin 
monooxygenases (FMOs), into TMA N-oxide (TMAO) (Wang et al., 2011). Animal model 
studies show direct provision of TMAO within the diet is pro-atherogenic, and similarly, 
provision of its dietary precursors (e.g. choline, carnitine, gamma butyrobetaine) also 
accelerates atherosclerosis development, but only in the setting of intact gut microbiota and 
TMA/TMAO generation (Wang et al., 2011; Koeth et al., 2013; Koeth et al, 2014). Recent 
studies involving genetic manipulation of FMO3, the major FMO responsible for converting 
TMA into TMAO (Bennett et al., 2013), further confirm the involvement of this meta-
organismal pathway in both atherosclerosis development and regulation of whole body 
cholesterol and sterol metabolism (Miao et al., 2015; Shih et al., 2015; Warrier et al., 2015). 
Moreover, an obligatory role for gut microbes in TMAO generation in humans was affirmed 
by two distinct studies involving ingestion of either isotope labeled phosphatidylcholine or 
isotope labeled carnitine as tracer before versus following exposure to an oral cocktail of 
poorly absorbed antibiotics to suppress intestinal microbes (Tang et al., 2013; Koeth et al., 
2013). Finally, an association between plasma TMAO levels and both the extent of coronary 
atherosclerotic plaque burden and CVD risks has been observed in multiple distinct clinical 
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studies (Wang et al., 2011; Tang et al., 2013; Tang et al., 2014; Lever et al., 2014; Tang et 
al., 2015).
Insights into the mechanisms through which the meta-organismal pathway responsible for 
TMAO production are associated with enhanced CVD risks have thus far focused on the 
involvement of TMAO and FMO3 in atherosclerotic plaque development, altered sterol and 
glucose metabolism, and changes in macrophage phenotype (Wang et al., 2011 ; Koeth et al., 
2013; Miao et al., 2015 ; Shih et al., 2015; Warrier et al., 2015). The involvement of gut 
microbes and TMAO in modulation of platelet function and thrombosis risks in vivo has not 
yet been reported.
RESULTS
Plasma TMAO levels predict incident thrombotic event risk (myocardial infarction and 
stroke)
We previously reported an association between plasma levels of TMAO and incident risk for 
the composite of major adverse cardiovascular events in a cohort of sequential stable 
subjects (n=4007) presenting to a cardiology clinic for elective diagnostic cardiac 
evaluations and for whom adjudicated longitudinal follow-up (3 year) for incident 
development of myocardial infarction (MI), stroke, death, or need for revascularization were 
collected (Tang et al., 2013). Initially, we therefore sought to reanalyze the clinical dataset 
and test whether an association between plasma levels of TMAO and incident risk for 
thrombotic events (MI or stroke) was observed. Plasma TMAO levels within the cohort 
showed a large dynamic range (0.06 to 312 µM; Figure 1A). TMAO showed a dose-
dependent association with increased cumulative burden of incident thrombotic events as 
illustrated by Kaplan-Meier survival analyses (Figure 1A). Importantly, the association 
between TMAO and incident thrombosis risk was observed even following adjustments for 
CVD history, traditional CVD risk factors, renal function and medication use (4th quartile 
level versus 1st quartile, adjusted 1.64-fold risk, p<0.001; Figure 1A).
TMAO directly enhances human platelet responsiveness to multiple agonists
The robust association observed between increasing TMAO levels and incident risk of 
thrombotic events in subjects served as impetus for further studies aimed at testing the 
hypothesis that TMAO may directly modulate platelet function. Initially, platelet-rich 
plasma was isolated from healthy volunteers with low levels of TMAO (all in first quartile, < 
2.4 µM), and the effect of physiologically relevant levels of exogenous TMAO (100 µM vs. 
vehicle) on platelet activation by the agonist ADP, as monitored by platelet aggregometry, 
was examined. While inter-individual variations in the magnitude of the effect of TMAO on 
platelet responsiveness to ADP stimulation was seen (Figure S1), overall, a leftward shift 
(p<0.0001) in the dose-response curve in the presence of high TMAO levels was observed 
(Figure 1B, left). Upon further examination, the enhancing effect of TMAO on platelet 
function was seen to be more generalizable, since similar results were observed using 
washed human platelets briefly incubated in the presence vs. absence of TMAO (100 µM) 
and varying doses of thrombin instead of ADP as agonist (Figure 1B, right).
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We next examined the effect of TMAO on platelet adhesion to collagen, a highly 
thrombogenic component of the subendothelium (Furie and Furie, 2008). Platelets within 
whole blood were fluorescently labeled, and adherence to the collagen surface of a 
microfluidic device under physiological shear forces was monitored in real time by 
microscopy, as described under Experimental Procedures. Figure 1C shows representative 
images of the collagen coated biochip under flow with whole blood from a typical subject at 
initial (t=0) and subsequent 1 minute interval periods of exposure, and illustrates the visible 
increase in fluorescent platelet adhesion noted in the presence of TMAO. Computer image 
assisted quantification of adherent platelets was employed, and cumulative data from 
multiple subjects (n=11) is shown in Figure 1D. TMAO significantly (p<0.0001) increased 
platelet adhesion within whole blood to immobilized collagen under physiological shear 
force. In the absence of collagen coating (±TMAO), platelet adhesion to the biochip surface 
was negligible (Figure 1D). Cumulatively, the above data demonstrate that physiological 
levels of TMAO directly enhance platelet responsiveness to multiple distinct agonists (ADP, 
thrombin and collagen).
TMAO enhances in vivo thrombosis
Since the enhancing effect of TMAO on platelet responsiveness is both rapid and direct, we 
reasoned that we should be able to induce a relatively acute rise in plasma TMAO levels 
within the physiologically observed range and simultaneously enhance in vivo thrombosis 
potential. To test this, plasma TMAO levels in mice were raised using intraperitoneal (i.p.) 
TMAO injection (vs. normal saline), and we quantified in vivo thrombosis potential using a 
carotid artery injury (FeCl3) model using fluorescently tagged platelets and intravital 
microscopy (we aimed to perform the thrombosis model when plasma TMAO was ~100 µM, 
as described under Experimental Procedures). Figure 1E shows representative images of 
thrombus development within the internal carotid artery at various time points following 
FeCl3 injury in a representative mouse injected with either TMAO or vehicle (normal 
saline). At the time of the carotid artery injury (2h following TMAO i.p. injection), a >10-
fold increase in plasma TMAO was observed that is well within the (patho)physiological 
range observed in humans (Figure 1E; 93.0±12.5 µM vs. 7.2±0.5 µM TMAO in TMAO vs. 
vehicle, respectively; p<0.001; n≥5 per group). As can be seen in Figure 1E, the rate of 
fluorescent thrombus formation is increased by TMAO. Further, the occlusion time, 
monitored by direct visualization of when platelets cease to pass downstream of the growing 
thrombus, is significantly (p<0.001) shorter in TMAO injected mice (Figure 1F).
TMAO promotes platelet hyperresponsiveness by enhancing stimulus-dependent release 
of Ca2+ from intracellular Ca2+ stores
Under resting conditions, platelets maintain a low intracellular cytosolic calcium ([Ca2+]i) 
level as they circulate through healthy vessels. However, at sites of vessel injury, platelets 
are rapidly activated by stimulus-dependent mobilization of [Ca2+]i, a precursor to thrombus 
formation and hemostasis (Rink and Sage, 1990; Furie and Furie, 2008). To explore how 
TMAO influences platelet [Ca2+]i washed platelets from healthy donors were loaded with 
Fura 2-AM, a calcium selective dye, to permit real time monitoring of [Ca2+]i at rest and 
following stimulus-dependent activation. Pre-incubation with TMAO showed no effect on 
resting platelet [Ca2+]i (Figure 2A). However, exposure to physiological levels of TMAO 
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enhanced submaximal thrombin-evoked augmentation of platelet [Ca2+]i in a dose-
dependent manner (Figure 2A and 2B). In parallel studies TMAO similarly increased 
submaximal ADP (1 µM) - triggered rise in platelet [Ca2+]i (Figure S2, panel A and B). The 
stimulatory effect of TMAO on platelet responsiveness to agonist was observed to occur 
rapidly, since only brief exposure (10 min) to TMAO significantly enhanced stimulus 
triggered rise in [Ca2+]i (data not shown) and platelet aggregation (Figure S2, panel C). To 
determine whether TMAO affects the release of Ca2+ from platelet stores or the entry of 
Ca2+ from extracellular media, we first examined [Ca2+]i in Fura 2-AM loaded platelets 
incubated with submaximal thrombin dose in media in the absence of free Ca2+ (and 0.1 
mM EGTA was added to the medium) in the presence vs. absence of TMAO. As seen in 
Figure 2C (left), under these conditions, platelet activation in the presence of TMAO 
resulted in an initial several-fold enhancement in rise of [Ca2+]i, indicating an intracellular 
source of Ca2+ is sufficient for TMAO induced augmentation in stimulus dependent rise in 
[Ca2+]i. With sustained incubation in media containing excess Ca2+ chelator, platelet [Ca2+]i 
eventually plummets, consistent with depletion of intracellular stores triggering plasma 
membrane Ca2+ channel opening. Subsequent addition of excess Ca2+ to the external media 
reveals sustained increase in [Ca2+]i, but no significant effect of TMAO on Ca2+ entry rate 
from the extracellular pool (Figure 2C and 2D). Finally, TMAO was seen to augment 
inositol-1,4,5-trisphosphate (IP3) signaling pathways in platelets with either submaximal 
thrombin (Figure 2E) or ADP (Figure 2F) as agonists by quantifying inositol phosphate 
levels.
Dietary choline enhances platelet responsiveness and in vivo thrombosis potential
Demonstration of a direct effect of TMAO on platelet function suggests that gut microbiota 
and specific dietary nutrients that enhance TMAO generation should similarly modulate 
platelet function and thrombosis potential in vivo. To explore this possibility, mice were 
placed on a chemically defined diet comparable to normal chow (0.08% total choline) versus 
the same chemically defined diet supplemented with either TMAO (0.12%) or choline (1%). 
In addition, the effect of gut microbial suppression with a cocktail of oral broad-spectrum, 
poorly-absorbed antibiotics (ABS) (Wang et al., 2011) was examined with both diets (Figure 
3). After 6 weeks, platelet-rich plasma was isolated from mice and both platelet 
responsiveness to ADP stimulation determined using ex vivo platelet aggregometry, and 
TMAO levels quantified. Figure 3A shows a representative tracing from the platelet 
aggregometry studies of a mouse from each dietary group using 1µM ADP as agonist, while 
data in Figure 3B represents scatter plots and cumulative statistical analyses of % maximal 
aggregation results at the sub-maximal ADP dose as agonist for each of the dietary +/− ABS 
groups of mice. Examination of plasma TMAO revealed elevated levels in mice provided 
dietary supplementation with either choline or TMAO. In parallel, ex vivo platelet 
aggregation induced by ADP stimulation was significantly increased in these groups (Figure 
3B). Moreover, the enhancing effect of dietary choline on platelet aggregation was 
suppressed in mice receiving oral ABS, which markedly reduces plasma TMAO levels 
(Figure 3A and 3B). Importantly, provision of ABS to the TMAO supplemented group did 
not have a significant effect on either plasma TMAO levels, or platelet aggregation (Figure 
3B). Figure 3C illustrates parallel independent studies examining platelet activation in 
response to different concentrations of ADP or different agonists (collagen or arachidonic 
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acid). Notably, TMAO supplementation similarly enhanced ex vivo platelet aggregometry 
responses to submaximal levels of each of the agonists examined (Figure 3C).
In further studies the impact of dietary choline, TMAO and gut microbiota on in vivo 
thrombosis potential were examined using the carotid artery FeCl3 injury model using an 
overall study design identical to that used for the ex vivo platelet aggregometry studies 
above (Figure 3D). Consistently, in vivo thrombosis potential, as monitored by time to blood 
flow cessation in the carotid artery following FeCl3 injury, was shortened (indicating a more 
prothrombotic phenotype) in mice with heightened TMAO levels (choline or TMAO 
supplemented diet groups) (Figure 3D). Importantly, the effect of dietary choline on in vivo 
thrombosis was inhibited by concurrent oral ABS administration, which suppresses the gut 
microbiota and TMAO levels (Figure 3D; TMAO levels in Figure 3B). We also examined 
the impact of each dietary intervention on platelet counts, along with other metabolic 
parameters (Table S1), and saw no differences to account for the observed effects on in vivo 
thrombosis potential. In a complementary set of studies, we employed an alternative trigger 
of platelet activation and thrombosis in vivo, photochemical injury using Rose Bengal as a 
photosensitizing agent (Figure 3E) (Furie and Furie, 2008). Mice were placed on the 
chemically defined chow diet (0.08% total choline) versus the same diet supplemented with 
either TMAO (0.12%) or choline (1%) for 1 week, at which point the Rose Bengal was 
injected, the mid portion of the common carotid artery was illuminated with a 1.5 mW green 
light laser and blood flow was continuously monitored by doppler, as described under 
Experimental Procedures. Notably, dietary TMAO or choline supplementation each 
markedly increased plasma TMAO levels, and were accompanied by significant shortening 
of occlusion time (Figure 3E).
We next sought to determine whether the enhancing effect of dietary choline 
supplementation on platelet function was due to a factor(s) that was contained within 
platelet-poor plasma, as anticipated for TMAO, or whether the platelets themselves showed 
altered responsiveness when recovered from mice chronically on the choline supplemented 
diet. Platelet-rich plasma from each group of mice was recovered and then further 
fractionated into a washed platelet versus platelet-poor plasma fraction under 
ultracentrifugation conditions that also removed microparticles and exosomes, as described 
under Experimental Procedures. As shown in Figure 3F, enhanced platelet aggregation 
responses in add-back/mixing studies revealed that the hyperresponsive phenotype followed 
the choline diet derived platelet-poor plasma. In contrast, the source of the washed platelets 
(chow vs. choline diet fed animals) failed to impact overall extent of platelet aggregation 
monitored.
Gut microbes play an obligatory role in choline diet dependent enhancement in 
thrombosis
To confirm a role for gut microbes in choline diet-dependent enhancement of platelet 
responsiveness in vivo, we performed in vivo thrombosis studies (FeCl3 induced carotid 
artery injury model) using germ-free C57BL/6J mice housed under sterile conditions, their 
conventional (microbe colonized) counterparts, or germ-free mice after conventionalization 
(housing in conventional cages to permit microbe colonization). All mice were maintained 
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on the indicated diets for 6 weeks, and plasma was recovered for TMAO analyses on the day 
of the in vivo thrombosis assay. As previously observed, conventional mice supplemented 
with either dietary choline or TMAO (relative to the control (chow) group) showed 
significant increases in plasma TMAO levels, and in parallel, enhanced thrombosis 
(reductions in carotid artery time to cessation of blood flow following FeCl3 injury; Figure 
4A). In contrast, within the germ-free mice, supplementation with choline no longer 
produced TMA (and hence TMAO) or the prothrombotic phenotype. Moreover, provision of 
dietary TMAO within the germ-free mice (bypassing the need for gut microbes to elevate 
TMAO) resulted in significant shortening in the time to cessation of blood flow (Figure 4A). 
Notably, germ-free mice that were subsequently conventionalized (placed in conventional 
cages allowing microbe colonization) at the start of the 6 week dietary exposure period, 
showed choline diet-dependent enhancement in plasma TMAO levels and accompanying 
pro-thrombotic phenotype compared with chow fed conventionalized mice (Figure 4A). 
Examination of the relationship between plasma TMAO levels and a quantitative measure of 
thrombosis potential (time to cessation of blood flow using the carotid artery injury model) 
across all groups of mice studied revealed a significant negative correlation (R=−0.62; 
p<0.001; Figure 4B).
Specific gut microbial taxa are associated with both TMAO levels and thrombosis potential
To identify microbial genera associated with dietary choline-induced enhancement in in vivo 
thrombosis potential, mice were maintained on either the chow (0.08% total choline; n=20) 
or choline supplemented diet (1.0% total choline; n=20) for 6 weeks and then plasma TMAO 
levels, in vivo thrombosis potential using the carotid artery injury model, and cecal 
microbial composition examined. Principal Coordinates Analysis of microbial DNA 
encoding 16S ribosomal RNA was initially used to visualize whether community differences 
were observed between cecal microbes in mice on the chow versus choline supplemented 
diets. Distinct (nonoverlapping) clusters were observed (Figure 4C, p<0.001 for Student’s t 
test with 1,000 Monte Carlo simulations) suggesting chronic exposure to supplemental 
dietary choline induced a significant rearrangement in the overall cecal microbial 
composition. Linear Discriminant Analysis (LDA) coupled with effect size measurements 
(LEfSe) further identified cecal microbial taxa that accounted for the greatest differences 
observed in mice on the distinct diets. In total, 8 taxa were identified through LEfSe 
analyses as being characteristic of choline vs. chow diet (Figure 4D), where choline diet 
significantly increased proportions of 3 genera (Figure S3, panels A, B and C) and decreased 
5 genera (Figure S3, panels D, E, F,G and H).
In further analyses of the detected cecal genera within all groups of mice, 9 taxa were 
identified whose proportions were significantly associated with plasma TMAO levels (FDR 
adjusted p≤0.1), and 15 taxa were identified whose proportions were significantly associated 
with in vivo thrombosis potential (i.e. occlusion time; FDR adjusted p≤0.1) (Table S2 and 
Figure S4, panel A). The proportions of 8 taxa were significantly associated with both 
plasma TMAO levels and occlusion time, and in every case, microbial taxa positively 
associated with higher plasma TMAO levels were associated with shorter time to blood flow 
cessation (more prothrombotic), whereas taxa significantly associated with reduced TMAO 
levels were associated with longer time to blood flow cessation (Table S2 and Figure S4, 
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panel A). Interestingly, the proportions of most of the identified bacterial taxa characteristic 
of a high choline diet were also positively associated with a pro-thrombotic phenotype 
(shorter occlusion time). For example, the proportion of Allobaculum, a high choline diet 
characteristic taxa, was significantly positively associated with TMAO levels and shortened 
internal carotid artery occlusion times (Figure 4E, left; Figure S4). In contrast, alternative 
bacterial taxa that showed significant reduction in proportion such as Candidatus 
Arthromitus or Lachnospiraceae were associated with both lower TMAO levels and an anti-
thrombotic phenotype (longer occlusion times) (Figure 4E, right; Figure S4).
Metagenomic analyses were also performed following shotgun sequencing of the cecal 
microbiota within mice from each of the three diets. Over 6000 species and strains were 
detected altogether. Table S3 lists the KEGG pathways that were present, indicating those 
that were identified in one or more samples and the significance of differences in abundance 
between the diets, and Figure S5 summarizes microbial pathways significantly different 
between cecal microbes recovered from the different dietary groups of mice. In addition to 
the choline utilization gene cluster identified in Desulfovibrio desulfuricans (Cracium and 
Balskus, 2012), several human gut microbiota reference species associated with TMA 
production, encoding the CutC/CutD, YeaW/X and CntA/B enzymes recently identified 
(Falony et al., 2015; Koeth et al., 2014) were also observed. Table S4 lists all of those 
detected in one or more samples in our study, as well as differences in abundance between 
the diets. In recent studies Romano and colleagues (Romano et al., 2015) examined 79 
common gut microbe isolates and tested these in vitro for choline consumption and TMA 
production. Of these, 8 were found to be TMA producers, and all 8 were present in the 
metagenomic data from the mice in our study: Anaerococcus hydrogenalis, Clostridium 
asparagiforme, Clostridium hathewayi, Clostridium sporagenes, Escherichia fergusonii, 
Proteus penneri, Providencia rettgeri, and Edwardsiella tarda. Of these, only the first three 
differed significantly between the chow and choline diets; however, surprisingly, these 
tended to be more abundant in mice from the chow vs. high choline diet groups (Table S4). 
These results underscore the complex community dynamic operating in vivo is more 
relevant to global TMA/TMAO production, as opposed to the in vitro ability of an individual 
microbial species to produce TMA from choline. Moreover, additional microbial TMA 
lyases no doubt exist that can contribute to TMA/TMAO production besides those already 
reported.
Cecal microbial transplantation studies demonstrate thrombosis potential is a 
transmissible trait
We next sought to test whether the effect of dietary choline on thrombosis potential is 
transmissible with microbial transplantation (i.e. fulfillment of an essential Koch’s postulate 
(Koch, 1880). We recently examined TMAO levels in a mouse diversity panel comprised of 
over 20 different inbred strains of mice, and identified C57BL/6J as a “high TMAO” 
producing atherosclerotic disease-prone strain, and NZW/LacJ as a “low TMAO” producing 
disease-resistant strain (Gregory et al., 2015). In addition, we successfully used cecal 
contents from these inbred strains of mice as donors of functionally distinct stable microbial 
communities in transplantation studies, revealing that both atherosclerosis susceptibility and 
TMA/TMAO production are transmissible traits (Gregory et al., 2015). Before further using 
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these inbred strains as donors in cecal microbial transplantation studies exploring thrombosis 
potential, we thought it important to first confirm that the high TMAO producing strain 
(C57BL/6J) showed shorter occlusion time (more pro-thrombotic phenotype) than the low 
TMAO producing strain (NZW/LacJ), particularly on a high choline diet. Conventional 
C57BL/6J and NZW/LacJ mice were maintained for 6 weeks on chemically defined chow 
(0.08% total choline) versus choline supplemented (1.0% total choline) diets. On the day of 
in vivo thrombosis assay, plasma TMAO levels in the C57BL/6J mice were over twice as 
high as those observed in the NZW/LacJ mice on the corresponding diet in both normal 
chow and choline supplemented diet arms of the study (Figure S6, panel A). Interestingly, 
whereas a choline supplemented diet fed to C57BL/6J mice provoked a significant 
prothrombotic phenotype (p=0.0002 relative to chow), the NZW/LacJ mice on the choline 
supplemented (versus chow) diet exhibited only a trend (p=0.07) toward reduced carotid 
artery occlusion time following FeCl3-induced injury (Figure S6, panel A).
Based upon the above results, we proceeded with cecal microbial transplantation studies 
using C57BL/6J (“high TMAO”, “pro-thrombotic”) and NZW/LacJ (“low TMAO”, “low 
thrombotic”) mice as cecal microbial donor strains, and germ-free mice (C57BL/6J) as 
recipients. For 6 weeks preceding the start of the study, all mice (both donors and germ-free 
recipients) were maintained on the chemically defined (sterile) chow diet. Following cecal 
microbial transplantation, recipients were individually housed in separate microisolators and 
maintained on sterile (irradiated) chow vs. choline supplemented diets, as described under 
Experimental Procedures (overall scheme is shown in Figure 5A). Successful transplantation 
of differential microbial choline TMA lyase enzyme activity in the donors (measured by 
conversion of d9-choline into d9-TMA in cecum) was observed in the recipients following 
transplantation (Figure 5B). In contrast, examination of hepatic FMO enzyme activity, which 
is responsible for converting TMA into TMAO (Wang et al., 2011; Bennett et al., 2013), 
revealed no significant differences between both donor mouse strains, and among the various 
recipient groups post cecal microbial transplantation (Figure S6, panel B). Results of plasma 
TMAO levels on day of sacrifice, platelet function (ex vivo platelet aggregometry) and in 
vivo thrombosis potential (FeCl3 carotid artery injury model) in each group of mice are 
shown in Figure 5C and D. First, as previously observed, germ-free recipients following 
microbial transplantation with C57BL/6J cecal contents showed a significant ~ 2-fold 
increase in plasma TMAO levels compared to recipients on the comparable diets receiving 
microbial transplantation with NZW/LacJ cecal contents (Figure 5C,D). Moreover, recipient 
mice following microbial transplantation with C57BL/6J cecal contents on the choline 
supplemented diet showed ~10-fold increase in plasma TMAO level and accompanying 
enhanced platelet responsiveness to submaximal ADP dose during platelet aggregometry 
studies compared with chow-fed controls (p<0.0001; Figure 5C). Similarly, recipients of the 
C57BL/6J cecal microbes maintained on the choline supplemented diet also showed 
significant shortening of time to blood flow cessation during in vivo thrombosis assay 
(p<0.0001; Figure 5D). In contrast, a blunted (relative to C57BL/6J) rise in TMAO in the 
recipients receiving NZW/LacJ cecal microbes and placed on choline supplemented diet was 
observed, with a correspondingly reduced effect of choline diet on both platelet 
responsiveness and in vivo thrombosis potential (Figure 5C,D).
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Transplanted cecal microbial taxa associate with TMAO levels and thrombosis potential
Cecal microbial composition in donors (on chow diet) and germ-free recipients post 
transplantation on the distinct diets (chow versus choline supplemented) was examined as 
before by sequencing microbial DNA encoding 16S ribosomal RNA and performing 
Principal Coordinates Analyses. Clear differences in community structure were visualized 
between cecal microbes recovered from the donors (Figure 6A). Further, following 
transplantation, recipients of C57BL/6J cecal microbes showed cecal microbial composition 
similar to the C57BL/6J donors, and recipients of NZW/LacJ cecal microbes show cecal 
microbial composition similar to the NZW/LacJ donors (Figure 6A). In addition, exposure 
to the high choline diet induced a shift in community composition within each recipient 
group, but the differences between (and similarities with their respective donor) the 
microbial community compositions in the respective recipients remained visible (Figure 
6A).
In further studies we examined whether the proportions of any cecal taxa in recipient mice 
from the above microbial transplantation study were significantly correlated with either 
plasma TMAO levels or in vivo thrombosis potential (occlusion time) at time of sacrifice 
(Figure S7). Of note, the proportions of several taxa previously identified in analyses of mice 
on chow versus choline supplemented diets as being associated with TMAO levels and in 
vivo thrombosis potential (Figures 4E, Figure S4, Table S2) were again observed to be 
significantly associated with TMAO levels and occlusion time. Specifically, proportions of 
three taxa in recipient cecal microbes were identified when grouped by dietary treatment as 
again being significantly associated with both plasma TMAO levels and occlusion time 
[Allobaculum with TMAO, p<0.0001, and with occlusion time, p=0.01 (Figure S7, panel B); 
Candidatus Arthromitus with TMAO, p<0.0001, and with occlusion time, p=0.007 (Figure 
S7, panel C); and Lachnospiraceae with TMAO, p<0.0001, and with occlusion time, p=0.01 
(Figure S7, panel D)].
LEfSe analyses was next performed to identify cecal microbial taxa that account for the 
greatest differences between C57BL/6J and NZW/LacJ donor mice (Figure 6B), and the 
relationships of these donor characteristic taxa with both plasma TMAO and in vivo 
thrombosis potential examined in recipients following cecal microbial transplantation. 
Interestingly, of the ten taxa identified as characteristic for C57BL/6J donors (Figure 6B, 
taxa depicted in red), examination of these in recipient cecal microbes revealed that the 
proportions of seven taxa either trended or were significantly positively associated with 
TMAO and negatively with time to cessation of flow (i.e. associated with a more “pro-
thrombotic” phenotype). Genus Prevotella and order YS2 from the Cyanobacteria phylum 
are examples of C57BL/6J donor characteristic taxa identified by the LEfSe analyses that in 
recipients were positively associated (after FDR adjustment) with TMAO and negatively 
with time to occlusive clot formation (Figure 6C, D). In similar analyses, of the fourteen 
taxa identified as being characteristic of the NZW/LacJ donors in LEfSe analyses (Figure 
6B, taxa depicted in blue), when examined in recipient cecal microbes, the proportions of 
eight taxa either trended or were significantly negatively associated with TMAO levels and 
positively associated with time to cessation of flow (i.e. less thrombotic phenotype). The 
genus Peptococcaceae is an example of a taxa identified as being characteristic of the NZW/
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LacJ donors and which was observed to be both significantly negatively associated with 
TMAO levels and positively associated with in vivo time to occlusive clot formation within 
recipients (Figure 6E).
DISCUSSION
The present studies reveal the interesting finding that gut microbes modulate thrombosis 
potential in vivo. They also expand upon our understanding of the relationship between 
TMAO and CVD risk. The TMAO meta-organismal pathway has been shown to possess 
numerous clinical and mechanistic links (Figure 7A) with both atherosclerotic plaque 
development and whole body cholesterol and sterol metabolism (Wang et al., 2011; Koeth et 
al., 2013; Koeth et al., 2014; Gregory et al., 2015; Miao et al., 2015; Shih et al., 2015; 
Warrier et al., 2015). Moreover, circulating levels of TMAO have been shown in multiple 
distinct clinical studies and cohorts to be associated with CVD risks (Wang et al., 2011; 
Tang et al., 2013; Lever et al., 2014; Wang et al., 2014a; Tang et al., 2015 ; Trøseid et al., 
2015), and targetted suppression of microbial TMA/TMAO production has recently been 
shown to inhibit diet induced atherosclerosis (Wang et al, 2015). The present studies expand 
upon these findings, and show that gut microbes, via generation of TMAO, can directly 
modulate platelet hyperresponsiveness and clot formation rate in vivo. A scheme illustrating 
the overall involvement of gut microbes and the TMAO meta-organismal pathway in platelet 
hyperresponsiveness and in vivo thrombosis potential, a critical determinant of patient 
vulnerability for adverse cardiac event risk, is illustrated in Figure 7A. Also shown are 
known effects of the gut microbial TMAO pathway on CVD, including the recent 
demonstration of adverse ventricular remodeling and heart failure risk (Organ et al., 2015), 
and arterial endothelial cell activation in vivo (Seldin et al., 2016). The influence of gut 
microbes on thrombosis risk via TMAO production requires the presence of an appropriate 
dietary input capable of producing TMA (e.g. foods rich in choline or phosphatidylcholine), 
the precursor for TMAO generation. Further, an obligatory role of gut microbes in choline 
dietenhanced thrombosis was confirmed both in studies using germ-free mice and in 
conventional mouse studies in the presence versus absence of oral poorly absorbed broad 
spectrum antibiotics. Cecal microbial transplantation studies confirm that both choline diet-
enhanced platelet responsiveness and in vivo thrombosis potential are transmissible traits. 
Finally, results of large scale human clinical studies with over 4000 subjects underscore the 
potential clinical significance of the pathway, since elevated TMAO levels are independently 
associated with incident risk for thrombotic events (myocardial infarction or stroke) in 
subjects, even following adjustments for multiple risk factors, medication use and CVD 
status.
The mechanisms through which dietary choline influences platelet responsiveness and 
function, impacting overall in vivo thrombosis risk, are illustrated in Figure 7B. First, a diet 
rich in choline alters microbial composition and function. Specifically, with choline 
supplementation, total cecal microbial choline TMA lyase activity was shown to increase, 
with parallel increases in both plasma TMAO levels and proportions of specific taxa 
associated with TMAO. The present studies also show that the effect of TMAO on platelet 
hyperresponsiveness is not stimulus specific; rather, multiple distinct agonists including 
ADP, thrombin, collagen and arachidonic acid all showed TMAO-dependent enhancement in 
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Ca2+ release from platelet intracellular stores and activation in the setting of submaximal 
agonist stimulation (Figure 7B). In addition, studies examining the effect of TMAO on IP3 
generation in platelets, a second messenger signaling molecule produced by various 
phospholipase C isoforms that triggers intracellular Ca2+ release leading to platelet 
activation, similarly showed TMAO-dependent enhancement. These observations 
collectively suggest the site of TMAO action in platelets is at a molecular level at or 
proximal to this step. Importantly, the effect of TMAO on platelet function was also dose-
dependent across the physiological range of TMAO concentrations observed in both humans 
and in animal models. Finally, the effect of TMAO on platelet reactivity and in vivo 
thrombosis was observed to be both rapid and reversible.
Despite the numerous findings and mechanistic insights revealed regarding the impact of 
TMAO on platelet function, the “chemical sensor” for TMAO within platelets remains 
unknown. Indeed, a receptor for TMAO in eukaryotic cells has not yet been reported. In 
contrast, TMA is a well-known ligand for an olfactory G-protein coupled receptor, trace 
amine-associated receptor 5 (TAAR5), which is specific for TMA and dimethylamine, but 
reportedly does not recognize either TMAO or numerous alternative methylamines 
(Wallrabenstein et al., 2013). Since orally ingested TMAO can in part be converted back to 
TMA by gut microbes, one might speculate that TMA, and thus TAAR5, might participate 
in the observed platelet phenotype. However, results of platelet aggregometry studies with 
direct addition of chemically pure TMAO, as well as studies employing germ-free mice and 
dietary TMAO supplementation, both strongly indicate that it is TMAO itself, and not TMA, 
that mediates the observed platelet hyperresponsiveness ex vivo, and the pro-thrombotic 
phenotype in vivo. Whether there is a dedicated receptor on the platelets for TMAO, or 
TMAO instead acts as an allosteric modulator of existing signaling pathways is unknown. 
TMAO is known to function as a small molecule chaperone mimetic, influencing protein 
conformation and function. Studies with isotope labeled TMAO reveal it can enter cells 
(data not shown), but its site of action in modulating platelet function is at present unknown. 
Biophysically, TMAO is rather unique and possesses both hydrophobic and hydrophilic 
properties and the known ability to alter protein confirmation and stability (Brown et al., 
1997; Singh et al., 2007). Discovery of the molecular receptor(s) that senses TMAO within 
cells like platelets is an area of intense interest.
In summary, the present work reveals the clinically relevant discovery that gut microbes, via 
generation of TMAO, participate in modulating platelet function and generation of a 
prothrombotic phenotype in vivo. The results thus suggest new potential therapeutic targets 
and refinement of nutritional interventions for the prevention of adverse cardiovascular event 
risk. It is remarkable that numerous large scale epidemiological studies have noted a 
relationship between a Western diet, which is enriched in known nutrient TMAO precursors 
(e.g. choline, phosphatidylcholine and carnitine), and enhanced risk for myocardial 
infarction, stroke and death (Iqbal et al., 2008; Rohrmann et al., 2013). It also is relevant that 
anti-platelet agents are a cornerstone of current pharmacological interventions for the 
treatment and prevention of acute complications of CVD. These interventions are, however, 
hampered by their potential for bleeding as a complication (Jennings, 2009). The present 
studies suggest that targeting the gut microbial TMAO pathway as a treatment strategy, 
whether it be via dietary manipulation, alteration in microbial community with a probiotic or 
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prebiotic, or direct pharmacological inhibition of microbial enzymes involved in TMA 
production, has the potential to temper platelet hyperresponsiveness associated with elevated 
TMAO. Moreover, such pharmacological interventions would, in contrast to existing anti-
platelet agents, be expected to reduce platelet hyperresponsiveness to normal range, and not 
induce impairment in overall platelet function. Thus, one could speculate that targeting this 
microbial pathway would foster a beneficial “anti-platelet” effect, attenuating pro-
thrombotic tendencies, but without enhanced bleeding complications as a consequence. 
Studies into this possibility represent an attractive future area of investigation. Further 
examination of the clinical utility of TMAO levels as an indication of subjects who may 
benefit from anti-platelet prophylaxis therapy with low dose aspirin or other platelet directed 
antithrombotic drugs is also an area of considerable interest.
EXPERIMENTAL PROCEDURES
More complete experimental procedures are provided in Supplemental Experimental 
Procedures.
General procedures and reagents
Reagents were purchased from Sigma unless otherwise stated. Protein concentration was 
determined by bicinchoninic acid assay (BCA) assay (Bio-Rad). Hepatic FMO activity was 
quantified as described previously (Bennett et al., 2013). Mouse plasma total cholesterol and 
triglycerides were measured using Abbott ARCHITECT platform model ci8200 (Abbott 
Diagnostics).
Ethical considerations
All animal model studies were approved by the Institutional Animal Care and Use 
Committee at the Cleveland Clinic. All study protocols and informed consent for human 
subjects were approved by the Cleveland Clinic Institutional Review Board. Informed 
consents were obtained from all subjects.
Mass spectrometry quantification of plasma and dietary analytes
Stable isotope dilution liquid chromatography with on-line tandem mass spectrometry 
(LC/MS/MS) was used for quantification of plasma TMA and TMAO, as well as the content 
of free ant total choline of all chemically defined diets, as previously described (Wang et al., 
2011; Wang et al., 2014b).
Human studies
The association between TMAO levels and incident thrombotic event risk was examined in 
the Genebank Study (Tang et al., 2013). Platelets from consenting healthy volunteers were 
drawn into citrate tubes. Donors were prescreened and confirmed to have fasting TMAO 
<2.5 µM the day of blood draw. Platelet-rich plasma, isolated human platelets and 
aggregometry studies were performed as described in Supplemental Experimental 
Procedures. Thrombosis studies in whole blood at physiological levels of shear stress were 
performed using the Cellix Microfluidics System (Cellix Ltd.,) with computer image 
assisted quantification of adherent platelets as described in Supplemental Experimental 
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Procedures. Inositol phosphate levels were quantified using the IP-One ELISA kit (Cisbio 
Bioassays) according to the manufacturer's instruction.
In vivo carotid artery thrombosis models
Two in vivo thrombosis models were used. Mice were typically placed for 6 weeks on the 
indicated chemically defined diets (± oral broad-spectrum antibiotics provided in the 
drinking water, where indicated) as previously described (Wang et al., 2011). For most 
studies, mice were subjected to common carotid artery injury by application of 10% FeCl3 
for 1 min (Chen et al., 2008). In alternative studies, a photochemical carotid artery injury 
model was used as described in Supplemental Experimental Procedures. In some 
experiments, plasma TMAO was acutely elevated by intraperitoneal injection (100 µl) of 
sterile stock solution (290 mM final in sterile water, pH adjusted to 7.4 using 0.1N HCl) or 
sterile normal saline, and the carotid artery thrombosis model was performed two hours 
later.
Intracellular Ca2+ measurements
Ratiometric fluorescence measurements were conducted with 8×108 washed human platelets 
re-suspended in Hank’s buffered salt solution supplemented with bovine serum albumin and 
glucose and after incubation with Fura 2-AM (1 µM) and removal of unabsorbed FURA 2-
AM. Changes in [Ca2+]i were monitored by measuring Fura 2-AM fluorescence using 
340/380 nm dual–wavelength excitation and an emission of 510 nm, as described in 
Supplemental Experimental Procedures.
Germ-free mouse studies
Germ-free C57BL/6J female mice bred and housed at the National Gnotobiotic Rodent 
Resource Center, University of North Carolina (UNC) were used in various studies. Mice 
were exposed to 3 weeks of the indicated chemically defined sterile diets as described in 
Supplemental Experimental Procedures. Conventionalization of germ-free mice and 
microbial transplantation studies were performed as described in Supplemental 
Experimental Procedures.
Microbiota studies
Cecal microbial community composition was assessed by sequencing 16S rRNA gene 
amplicons (Gregory et al., 2015), and metagenomic analyses were performed as described in 
Supplemental Experimental Procedures, following shotgun sequencing of cecal microbes. 
Metagenomic data are deposited in MG-RAST-Argonne National Laboratory (http://
metagenomics.anl.gov/) and can be accessed through project name: Platelet function and 
TMAO.
Statistical analysis
Detailed statistical methods are described in Supplemental Experimental Procedures. All 
studies were repeated at least 3 independent times with the number of biological replicates 
(animal numbers) for a given experiment shown. Kaplan-Meier survival plots and Cox 
proportional hazards analysis were used to determine Hazard ratio (HR) and 95% confidence 
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intervals (95%CI) for thrombotic event (MI and stroke) risk stratified according to TMAO 
quartiles. Adjustments were made for individual traditional risk factors including age, sex, 
SBP, LDL, HDL, triglycerides, smoking, diabetes, estimated creatinine clearance, 
medications, and CVD status. All data were analyzed using R 3.1.0 (Vienna, Austria) and 
JMP (SAS Institute). For all statistical tests p < 0.05 was considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Elevated TMAO levels predict incident risk for thrombotic events in human 
subjects
• TMAO enhances submaximal stimulus-dependent platelet activation
• Dietary choline, gut microbes, and TMAO are linked to thrombotic potential in 
vivo
• Microbial transplantation shows that thrombosis potential is a transmissible trait
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Figure 1. TMAO is associated with thrombosis potential
(A) Relationship between plasma TMAO level and incident (3 year) thrombotic event (MI or 
stroke) risk in sequential subjects undergoing elective diagnostic coronary angiography. 
Kaplan–Meier survival analyses and Cox proportional hazards regression analyses were 
used for time-to-event analysis to determine adjusted Hazard ratio (HR) and 95% confidence 
intervals (95%CI). (B) Effect of TMAO on dose response curves for ADP- (left) or 
thrombin- (right) induced platelet activation monitored using platelet aggregometry. (C and 
D) Platelet adhesion in whole blood to a microfluidic chip surface (± collagen coating) 
Zhu et al. Page 19
Cell. Author manuscript; available in PMC 2017 March 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
under physiological sheer conditions ± TMAO, with (C) representative images of platelet 
adhesion at the indicated times; and (D) adherent platelet area per µm2 of chip surface. (E 
and F) In vivo thrombosis potential using the FeCl3-induced carotid artery injury model in 
response to TMAO (vs. normal saline) injected i.p. into mice. Plasma TMAO levels at time 
of thrombosis model are indicated. (E) Shown are representative vital microscopy images of 
carotid artery thrombus formation at the indicated time points following arterial injury, and 
TMAO levels (n≥5 each group); and (F) time to cessation of blood flow in mice from the 
indicated dietary groups. Bar represents mean time to cessation of blood flow within the 
indicated group. Significance was measured with either log rank or unpaired Student’s t test. 
The number of independent biological replicates (n = subjects or animals per group) in all 
panels are shown. Data are presented as mean ± SEM (B,D,E,F). Linear mixed effect models 
were used to analyze the repeated measure data in panel D. A Mann-Whitney test was used 
to compare the time to cessation of flow between the TMAO and control groups. See also 
Figure S1.
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Figure 2. TMAO augments stimulus-dependent release of Ca2+ from intracellular stores in 
human platelets
(A and B) Thrombin evoked changes in intracellular calcium concentration [Ca2+]i in Fura 
2-AM loaded washed human platelets incubated with the indicated amounts of TMAO. (A) 
Representative fluorescent signal from a single subject’s platelet preparation; and (B) mean 
± SEM results from n=4 subjects are shown (*, p<0.05 for comparison with vehicle). (C and 
D) Fluorescence ratio of Fura-2 loaded platelets incubated in medium supplemented with 
TMAO or vehicle. Cells were first stimulated at the indicated time with a sub-maximal 
thrombin dose in a Ca2+-free medium, and then where indicated, Ca2+ was added to the 
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medium. Representative (C) fluorescent signal and (D) mean fluorescence ± SEM (n=4 
donors) are shown. (E and F) Washed human platelets pre-incubated (30 min, 22°C) with the 
indicated concentrations of TMAO wer e stimulated with sub-maximal levels of either (E) 
thrombin or (F) ADP, and then platelet IP1 concentrations determined. Data shown represent 
mean ± SEM (n=4 donors each). Linear mixed effect models were used to analyze the 
repeated measure data. A Wilcoxon Signed-Rank Test was used to conduct pairwise 
comparisons. See also Figure S2.
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Figure 3. Dietary choline, via gut microbe-generated TMAO, enhances platelet responsiveness 
and promotes a prothrombotic phenotype
Mice were fed the indicated diets ± oral broad-spectrum antibiotics (ABS). (A, B) Platelet 
aggregometry was monitored in platelet-rich plasma following addition of sub-maximal 
(1µM final) ADP; or (D) in vivo thrombosis potential was quantified using the FeCl3-
induced carotid artery injury model. (A) Representative aggregation tracing in response to 
sub-maximal ADP dose from a mouse within each group, along with the corresponding 
plasma TMAO level. (B) Aggregation (% of max amplitude of aggregation) in response to 
ADP, along with plasma TMAO levels, for each group (n>9 each). (C) Aggregation 
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responses to the indicated submaximal concentrations of agonist (ADP, collagen or 
arachidonic acid, AA) in platelet-rich plasma recovered from mice on the indicated diets 
(n≥5). (D and E) Time to occlusive thrombus formation in either the (D) FeCl3-induced 
carotid artery injury model, or (E) photochemical injury-induced carotid artery injury model. 
Bar (B,D,E) represents mean value for the indicated group. TMAO levels are reported as 
mean ± SEM. (F) Aggregation responses to ADP (1µM) within the indicated mixtures of 
washed platelets and platelet-poor plasma prepared from mice on the indicated diets. Plasma 
TMAO levels (mean± SEM) of mice on the indicated diets is also shown. Data shown are % 
of max amplitude of aggregation (± SEM; for n≥=5 each). For significance, a Kruskal Wallis 
test was used for multiple group comparison and a Mann Whitney test was used for two 
group comparisons. See also Table S1.
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Figure 4. Microbial taxa associated with choline diet-induced TMAO generation and a 
prothrombotic phenotype
(A) Germ-free mice, conventionally reared mice, and germ-free mice subsequently 
conventionalized (all groups female, 4 week old, C57BL/6J), were fed the indicated sterile 
diets for 6 weeks and then both in vivo thrombosis potential (FeCl3 carotid artery injury 
model) and plasma TMAO levels were assessed. TMAO data represent mean ± SEM. (B) 
Correlation (Spearman) between plasma TMAO levels and time to cessation of blood flow 
among mice in all groups. (C) Microbial DNA encoding 16S rRNA was analyzed from 
cecum of mice in the indicated diet groups. Principal coordinates analyses demonstrate 
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distinct cecal microbial composition between groups (p < 0.001 for Student’s t test with 
1,000 Monte Carlo simulations). Each data point represents a sample from a distinct mouse 
projected onto the first three principal coordinates (percent variation explained by each PCo 
is shown in parentheses). (D) Linear Discriminant Analysis (LDA) Effect Size (LEfSe) 
identified taxa most characteristic (increased abundance) in chow (green) and choline (red) 
fed groups. (E) Example of choline diet group characteristic taxon (Allobaculum) and chow 
characteristic taxon (Candidatus Arthromitus) whose proportions are associated with both 
plasma TMAO levels and time to cessation of blood flow (occlusion time). A Kruskal Wallis 
test was used for multiple group comparison and a Mann Whitney test was used for two 
group comparison. See also Figure S3, Figure S4, Figure S5 and Tables S2–S4.
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Figure 5. Thrombosis potential is a transmissible trait
(A) Scheme illustrating cecal microbial transplant study design. Germ-free C57BL/6J mice 
(recipients) had cecal microbes introduced by gastric gavage from conventionally reared 
C57BL/6J (high TMA/TMAO producer) and NZW/LacJ (low TMA/TMAO producer) 
donors. Recipients (with and without microbe transplants) were placed on sterile chemically 
defined chow (0.08% choline) vs. choline supplemented (1.0% total) diets. (B) Cecal choline 
TMA lyase enzyme activity was quantified in donor mice (left panel), and recipient germ-
free mice without (middle) or following (right) microbial transplantation and maintenance 
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on the indicated diets within individual gnotobiotic isolators. Platelet function was assessed 
following microbial transplantation in the indicated numbers of recipient mice both by (C) 
ex vivo monitoring of aggregation response to ADP (1 µM), and (D) in vivo measuring of 
time to occlusive thrombus formation using the FeCl3-induced carotid artery injury model. 
(B,C and D) Plasma TMAO levels (mean ±SEM) were also determined at completion of all 
studies. For significance, a Kruskal Wallis test was used for multiple group comparison and 
a Mann Whitney test was used for two group comparison. See also Figure S6.
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Figure 6. Characterization of donor-characteristic cecal microbiota associated with TMAO and 
in vivo thrombosis potential in recipients following microbial transplantation
Intestinal microbial community composition was assessed by (A) Principle coordinates 
analysis for donor and recipient mouse strains on the indicated diets. (B) Linear 
Discriminant Analysis (LDA) Effect Size (LEfSe) analyses were performed to identify taxa 
most characteristic (increased abundance) in NZW/LacJ and C57BL/6J donors. (C) 
Illustration of three taxa identified in recipient cecal microbes whose proportions are 
significantly associated with both plasma TMAO levels and occlusion time when grouped by 
dietary treatment (blue squares, recipients of NZW/LacJ donor cecal microbes; red circles, 
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recipients of C57BL/6J microbes). Values in both x and y directions are plotted as mean±SE. 
Significance was determined using unpaired Student’s t test. See also Figure S7 and Table 
S5.
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Figure 7. Summary schemes illustrating gut-microbial involvement in development of platelet 
hyperresponsiveness and athero-thrombotic heart disease
(A) Global schema illustrating metaorganismal pathway linking dietary sources of choline 
abundant in a Western diet, gut microbiota and host hepatic FMOs, resultant TMAO 
production, and subsequent development of hyperresponsive platelet phenotype and 
enhanced thrombotic event risk. Also shown are reported pro-atherosclerotic effects of 
TMAO and the potential involvement of TMAO in development of vulnerable plaque. EC, 
endothelial cell; FMOs, flavin monooxygenases; M[phage], macrophage; TMA, 
trimethylamine; TMAO trimethylamine N-oxide. (B) Chronic exposure to a diet rich in 
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choline leads to a shift in the gut microbial composition and function, with consequent 
enhancement in host TMAO plasma levels. Platelet exposure to high levels of TMAO 
enhances sub-maximal stimulus (thrombin, ADP, collagen) evoked release of intracellular 
calcium stores, and platelet hyperresponsiveness. ADP, adenosine diphosphate; GPVI, 
glycoprotein VI; G<q>, G protein q; IP<3>, inositol 1,4,5-triphosphate; IP<3>R, Inositol 
1,4,5-triphosphate receptor; P2Y12, purinergic receptor P2Y12; PAR, protease activated 
receptor; PLC, phospholipase C; PIP2, phosphatidylinositol 4,5-bisphosphate.
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